Cargando…

Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial

DNA vectors have been widely used as a priming of poxvirus vaccine in prime/boost regimens. Whether the number of DNA impacts qualitatively or quantitatively the immune response is not fully explored. With the aim to reinforce T-cell responses by optimizing the prime-boost regimen, the multicentric...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lévy, Yves, Lacabaratz, Christine, Ellefsen-Lavoie, Kim, Stöhr, Wolfgang, Lelièvre, Jean-Daniel, Bart, Pierre-Alexandre, Launay, Odile, Weber, Jonathan, Salzberger, Bernd, Wiedemann, Aurélie, Surenaud, Mathieu, Koelle, David M., Wolf, Hans, Wagner, Ralf, Rieux, Véronique, Montefiori, David C., Yates, Nicole L., Tomaras, Georgia D., Gottardo, Raphael, Mayer, Bryan, Ding, Song, Thiébaut, Rodolphe, McCormack, Sheena, Chêne, Geneviève, Pantaleo, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319597/ https://www.ncbi.nlm.nih.gov/pubmed/32589686 http://dx.doi.org/10.1371/journal.ppat.1008522

Ejemplares similares

A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial
por: Lévy, Y., et al.
Publicado: (2021)

rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1
por: Montefiori, DC, et al.
Publicado: (2012)

OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial
por: Salmon-Céron, D, et al.
Publicado: (2009)

Correction for Kibler et al., “Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC”
por: Kibler, Karen V., et al.
Publicado: (2019)

Optimization and evaluation of Luminex performance with supernatants of antigen-stimulated peripheral blood mononuclear cells
por: Surenaud, Mathieu, et al.
Publicado: (2016)

Cellular Immune Responses Induced with Dose-Sparing Intradermal Administration of HIV Vaccine to HIV-Uninfected Volunteers in the ANRS VAC16 Trial
por: Launay, Odile, et al.
Publicado: (2007)

Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design
por: Richert, Laura, et al.
Publicado: (2014)

Improved NYVAC-Based Vaccine Vectors
por: Kibler, Karen V., et al.
Publicado: (2011)

Decreased HIV-Specific T-Regulatory Responses Are Associated with Effective DC-Vaccine Induced Immunity
por: Brezar, Vedran, et al.
Publicado: (2015)

Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors
por: Quakkelaar, Esther D., et al.
Publicado: (2011)

Immune Alterations in a Patient with SARS-CoV-2-Related Acute Respiratory Distress Syndrome
por: Bouadma, Lila, et al.
Publicado: (2020)

IL-7 abrogates memory T regulatory cell functions by modulation of CD39/ATP axis in vitro and in vivo in HIV infected and non-infected patients
por: Younas, M, et al.
Publicado: (2012)

Negative modulation of suppressive HIV-specific regulatory T cells by IL-2 adjuvanted therapeutic vaccine
por: Brezar, Vedran, et al.
Publicado: (2017)

Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study
por: Perdiguero, Beatriz, et al.
Publicado: (2022)

Anti-HIV potency of T-cell responses elicited by dendritic cell therapeutic vaccination
por: Surenaud, Mathieu, et al.
Publicado: (2019)

rAd5 prime/NYVAC-B boost regimen is superior to NYVAC-B prime/rAd5 boost regimen for both response rates and magnitude of CD4 and CD8 T-cell responses
por: Bart, P, et al.
Publicado: (2012)

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
por: Pantaleo, Giuseppe, et al.
Publicado: (2019)

Immunodeficiency, HIV RNA plasma viral load and risk of AIDS-defining and non-AIDS-defining neoplasia, ANRS CO3 Aquitaine Cohort (1998–2006)
por: Bruyand, M, et al.
Publicado: (2009)

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
por: Harari, Alexandre, et al.
Publicado: (2008)

No Positive Association between Vitamin D Level and Immune Responses to Hepatitis B and Streptococcus pneumoniae Vaccination in HIV-Infected Adults
por: Viard, Jean-Paul, et al.
Publicado: (2016)

Temporal trends of population viral suppression in the context of Universal Test and Treat: the ANRS 12249 TasP trial in rural South Africa
por: Larmarange, Joseph, et al.
Publicado: (2019)

ANRS0001S COV-POPART : Réponse humorale des personnes vivant avec le VIH à 12 mois d'un schéma de vaccination Covid-19
por: Loubet, P., et al.
Publicado: (2023)

Poxvirus tropism
por: McFadden, Grant
Publicado: (2005)

Poxvirus Recombination
por: Evans, David Hugh
Publicado: (2022)

Zoonotic poxviruses()
por: Essbauer, Sandra, et al.
Publicado: (2010)

OA021-01. Construction and characterization of replication competent attenuated NYVAC-based vectors as potential HIV vaccines
por: Jacobs, B, et al.
Publicado: (2009)

Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways
por: Gómez, Carmen Elena, et al.
Publicado: (2017)

Low CD4/CD8 Ratio Is Associated with Non AIDS-Defining Cancers in Patients on Antiretroviral Therapy: ANRS CO8 (Aproco/Copilote) Prospective Cohort Study
por: Hema, Mariam Noelie, et al.
Publicado: (2016)

The impact of population dynamics on the population HIV care cascade: results from the ANRS 12249 Treatment as Prevention trial in rural KwaZulu‐Natal (South Africa)
por: Larmarange, Joseph, et al.
Publicado: (2018)

The Evolution of Poxvirus Vaccines
por: Sánchez-Sampedro, Lucas, et al.
Publicado: (2015)

Decoding poxvirus genome
por: Yang, Zhilong, et al.
Publicado: (2015)

Severe Morbidity According to Sex in the Era of Combined Antiretroviral Therapy: The ANRS CO3 Aquitaine Cohort
por: Hessamfar, Mojgan, et al.
Publicado: (2014)

CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death
por: Lévy, Yves, et al.
Publicado: (2021)

Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection
por: Alexandre, Marie, et al.
Publicado: (2022)

CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death
por: Lévy, Yves, et al.
Publicado: (2022)

84. One-month Humoral Response Following Two Doses of Covid-19 Vaccines in Specific populations – ANRS0001S COV POPART Cohort Study
por: LOUBET, Paul, et al.
Publicado: (2022)

Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax
por: Midgley, Claire M., et al.
Publicado: (2008)

A safer poxvirus vaccine
por: Bashyam, Hema
Publicado: (2008)

Lipid Membranes in Poxvirus Replication
por: Laliberte, Jason P., et al.
Publicado: (2010)

Detection of Infectious Poxvirus Particles
por: Nitsche, Andreas, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_pmcs4apvio9ds1a533184f24ti